

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

VOLUNTARY ANNOUNCEMENT ESTABLISHMENT OF EXTERNAL SCIENTIFIC ADVISORY BOARD

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Sirnaomics Ltd. (the “**Company**” together with its subsidiaries, the “**Group**”) on a voluntary basis.

On July 21, 2026, the Company established an external Scientific Advisory Board (the “**SAB**”) to provide independent, authoritative scientific guidance for the Group’s therapeutic pipeline research and development programs. The SAB comprises five internationally renowned multidisciplinary experts with in-depth expertise covering RNA delivery technology, RNAi drug discovery, oncology research and development (“**R&D**”), clinical translational medicine, Chemistry, Manufacturing, and Controls (“**CMC**”) activities, and global pharmaceutical regulatory compliance.

1. Dr. David Evans, Ph.D. — Co-founder of the Company and core developer of the Group’s polypeptide nanoparticle (PNP) delivery platform, bringing over 30 years of specialized experience in RNA mechanism research and novel drug discovery. Dr. David Evans earned his B.Sc. (Hons) and Ph.D. in Biochemistry from Imperial College London and completed postdoctoral fellowships at the University of Maryland and St. Louis University School of Medicine.
2. Dr. Dmitry Samarsky, Ph.D. — Distinguished specialist in oligonucleotide therapeutics, former Chief Technology Officer of the Company and inventor of the proprietary GalAhead™ delivery platform, with a wealth of expertise in novel delivery system

iteration and optimization. Dr. Dmitry Samarsky earned his Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts and conducted post-doctoral training at UMass Medical School as an H. Arthur Smith Fellow.

3. Dr. Johnson Yiu-Nam Lau, MBBS, MD, FRCP, FHKCP, FHKAM — Seasoned physician and biotech executive with extensive experience in securing regulatory approvals for multiple novel drugs from the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency (EMA), and the Therapeutic Goods Administration (TGA), along with deep insights into biotech capital operations and commercial product management. Dr. Johnson Yiu-Nam Lau earned his medical degrees (MBBS, MD) from the University of Hong Kong and is a Fellow of the Royal College of Physicians (London), the Hong Kong Academy of Medicine and the Hong Kong College of Physicians.
4. Dr. Archie Tse, M.D., Ph.D. — President, Head of Research & Development at Adlai Nortye, Senior executive leader in oncology R&D, with distinguished experience working at Merck, Daiichi-Sankyo and CStone Pharmaceuticals, specializing in the research and industrial transformation of small-molecule drugs, monoclonal antibodies, ADCs and tumor vaccines. Dr. Archie Tse earned his Doctor of Medicine, Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California.
5. Dr. Audrey Jia, M.D., Ph.D. — Former senior CMC reviewer at the FDA, possessing authoritative expertise in global cross-border regulatory strategies for Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) filings, as well as end-to-end Good Manufacturing Practice (GMP) compliance management. Dr. Audrey Jia trained as a medical professional at Peking University before earning her Ph.D. at Emory University and master’s degree in Regulatory Affairs at Johns Hopkins University. She is certified by the Educational Commission for Foreign Medical Graduates (ECFMG) and has passed the United States Medical Licensing Examination (USMLE).

The Company extends a sincere welcome to all distinguished experts joining the SAB. The diversified industrial experience and global strategic vision of the SAB members will deliver objective, independent, and high-value professional perspectives, facilitating the continuous enrichment and optimization of the Group's therapeutic pipeline, and further expanding its global high-end scientific research collaboration ecosystem.

By order of the Board

Sirnaomics Ltd.

Dr. Poon Hung Fai

Chairman and Executive Director

Hong Kong, July 21, 2026

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Dr. Yin Huijun as non-executive Director, and Mr. Wong Yu Shan Eugene, Dr. Zhang Peng and Ms. Lo Yee Hang as independent non-executive Directors.